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Although intensive lifestyle interventions can achieve substantial reductions in body weight in the context of randomized controlled trials, 4 results from real-life primary care settings have been disappointing. 5 Moreover, in response to body weight loss, physiological counter-regulatory mechanisms, such as compensatory changes in energy intake and expenditure, undermine the long-term maintenance of body weight loss. 6 While pharmacological treatments may augment initial body weight loss and/or maintenance of body weight loss alongside behavioural interventions, there are concerns as to their longer-term effectiveness and safety. 7 Consequently, an unmet need exists for novel body weight loss interventions, including pharmacotherapies, used singly or in combination, that provide durable efficacy and are safe and well tolerated. diuresis, but with a compensatory appetite increase, 11, 12 whereas GLP1RAs reduce appetite and delay gastric emptying. 13 The SGLT2 inhibitor dapagliflozin and the GLP-1RA exenatide consistently reduce body weight in patients with T2D, which is maintained for up to 2 [14] [15] [16] and 6 years, [17] [18] [19] respectively.
The differing and possibly complementary mechanisms of action of dapagliflozin and exenatide may be particularly effective when these agents are used in combination to achieve sustained body weight loss and prediabetes reduction.
We previously reported the 24-week results of a phase 2 randomized placebo-controlled study comparing dual therapy with oral dapagliflozin 10 mg once daily (DAPA) and subcutaneous exenatide 2 mg once weekly (ExQW) vs placebo (PBO) in obese adults without diabetes (N = 50). 20 Those receiving DAPA + ExQW lost weight (−4.5 kg), whereas those receiving PBO did not (−0.4 kg), and 36% vs 0% of participants, respectively, achieved ≥5% body weight loss.
Body weight loss with DAPA + ExQW was largely accounted for by reduction in adipose tissue volume as assessed with magnetic resonance imaging (MRI). Improved glycaemic control and reduced blood pressure were also observed with DAPA + ExQW. No unexpected tolerability issues were found with the combination in this small proof-of-concept study. 20 Participants completing the 24-week study who had adhered to the protocol were offered a further 28 weeks of treatment with DAPA +
ExQW in an open-label extension of this study. Outcomes evaluated included change in body weight, body composition by MRI, measures of glycaemic control and cardiovascular risk, and safety and tolerability.
2 | METHODS
| Study design and participants
The design of this phase 2a study evaluating the efficacy and safety of dual therapy with DAPA + ExQW in obese participants without diabetes (ClinicalTrials.gov identifier: NCT02313220) has been published previously. 20 Briefly, this was an investigator-initiated 24- week, randomized, parallel-group, double-blind, placebo-controlled trial followed by an optional 28-week open-label phase during which all participants received active treatment and had study visits at week 38 and 52 ( Figure 1A ). It was conducted at a single centre in 
| Outcomes
Details of outcome measures have been published previously 20 ; however, a brief description is provided below. 
| Efficacy

| Safety
Reports of adverse events (AEs) were collected and coded using 
| Statistical methods
Primary, secondary and exploratory efficacy endpoints were analysed with an intention-to-treat (ITT) approach, using all available data comprising the full analysis set. To assess potential bias from differential dropout rates in this delayed-start study, 21 sensitivity analyses were conducted for the primary endpoint. For further details, see File S1 (Sensitivity Analysis Methods; Sensitivity Analysis Results).
All statistical analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, North Carolina). CIs and P values were unadjusted for multiple comparisons. (Table S1 in File S1). One participant in each treatment arm, neither of whom entered the study extension, were using concomitant lipid-lowering agents on entering the 0-to 24-week study. Two participants, both in the PBO ! DAPA + ExQW group, received atorvastatin at week 13 and at initiation of the extension, respectively. In the PBO ! DAPA + ExQW group, antihypertensives were newly prescribed or increased in 4 and 2 participants during the 0-to 24-and 24-to 52-week periods, respectively. In the continued DAPA + ExQW group, 3 participants altered use of antihypertensives during the 0-to 24-week period (1 discontinued, 1 discontinued and then restarted, and 1 received a new prescription) and none altered use of antihypertensives thereafter. shown in Figure S1 of File S1.
| Waist circumference
Waist circumference was significantly reduced at 52 weeks for both the DAPA + ExQW and PBO ! DAPA + ExQW groups (−7.3 and −6.7 cm, respectively). A similar finding was evident for waist-to-hip ratio (Table 1) .
| MRI of body composition
Among participants continuing on DAPA + ExQW, total adipose tissue reduction achieved at 24 weeks (−3.8 L) was sustained at 52 weeks (−5.3 L), with some additional total adipose tissue loss from 24 to 52 weeks (−1.5 L) that did not reach statistical significance (Table 1 , Figure 2E ). Similar findings were observed for abdominal visceral and subcutaneous adipose tissue volumes (Table 1, Figure 2E ).
Numeric reductions in liver fat percent units in participants continuing on DAPA + ExQW did not reach statistical significance at either 24 or 52 weeks (Table 1) . Mean ( Figure S2A in File S1) and individual trajectories of change in liver fat percent units for DAPA + ExQW ( Figure S2B in File S1) and PBO ( Figure S2C in File S1) are presented in Figure S2 of File S1.
| Glycaemic variables
Among participants continuing on DAPA + ExQW, reduction in FIGURE 2 Changes in body weight, body composition, abdominal adipose tissue, and SBP. A, Primary endpoint: adjusted mean change from week 0 in body weight (kg) at 24 and 52 weeks. B, Secondary endpoint: adjusted mean percentage change from week 0 in body weight (%) at 24 and 52 weeks. C, Individual participant trajectories of percent change in body weight over 52 weeks in dapagliflozin/exenatide-treated participants (*although 9 participants discontinued DAPA + ExQW, 1 of these participants attended the final visit for weight measurement). D, Corresponding trajectories in placebo-treated participants. E, Adjusted mean change from week 0 in total lean and total adipose tissue volume and in visceral subcutaneous adipose tissue volume at 24 and 52 weeks among participants continuing on DAPA + ExQW throughout the study. F, Adjusted mean change from week 0 in SBP (mm Hg) over 24 and 52 weeks. Analyses in panels A, B, E and F employed mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment-by-week, sex and baseline value. CI, confidence interval; DAPA + ExQW, dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly; PBO, placebo; SBP, systolic blood pressure; w, week(s) prediabetes (68% ! 34.8%) at 24 weeks were sustained at 52 weeks (−2.2 mmol/L, 35.3%, 13.3% and 35.3%, respectively) (Table 1, Figure 3C ).
| Vital signs
In this predominantly normotensive population at baseline (mean baseline SBP, 134 mm Hg), 20 participants continuing on DAPA + ExQW showed a significant reduction in SBP at 24 weeks (−9.8 mm Hg), which was sustained at 52 weeks (−12.0 mm Hg) (Table 1, Figure 2F ).
No changes in DBP were observed for either treatment group. Heart rate was unchanged in the continued DAPA + ExQW group, but increased in the PBO ! DAPA + ExQW group from 0 to 52 weeks (Table 1) .
| Fasting serum lipids
No significant changes in high-density lipoprotein cholesterol were observed in participants in either treatment group. Low-density lipoprotein cholesterol decreased significantly from 0 to 52 weeks in both groups, and triglycerides decreased significantly from 0 to 52 weeks in the continued DAPA + ExQW group (Table 1) .
| Safety and tolerability
All participants in both groups reported at least 1 AE by week 52 (Table 2 ). In the continued DAPA + ExQW group, serious AEs (Table 2) . No other clinically significant changes in laboratory assessments were observed in either treatment group over 52 weeks, apart from a small increase in haemoglobin at 52 weeks in the PBO ! DAPA + ExQW group (Table 2) . No AEs of pancreatitis or pancreatic cancer were reported. A high degree of motivation is required to achieve both initial body weight loss and, especially, to sustain this loss in the face of opposing influences, including physiological counter-regulatory mechanisms seeking to regain body weight, 6,22 chronic hunger/food craving, 23 and ongoing sociocultural pressures (eg, sedentary occupations) that impair consolidation of healthy lifestyles. 1 Given the unmet need for novel pharmacotherapies to achieve and sustain body weight loss, and their established efficacy and safety in patients with T2D, the combination of an SGLT2 inhibitor (urinary caloric loss) and a GLP-1RA (appetite suppression) may be an attractive option to assist obese individuals in reducing body weight as either standalone therapy (eg, when individuals must lose sufficient body weight to initiate an exercise programme) 24 or an adjunct to lifestyle intervention.
In this study of obese adults without diabetes who did not undergo a formal lifestyle intervention, a mean body weight loss of b AEs that led to treatment discontinuation in the DAPA + ExQW group over 52 weeks were abdominal pain, injection-site pruritus/mass, nausea, dizziness, fatigue and eye allergy. would be similar to those at 24 weeks had there been a continuing placebo arm, estimated placebo-corrected changes at 52 weeks and the proportion achieving body weight loss ≥5% would be −5.3 kg and 40.0% (ITT percentage), respectively.
However, the current study did not employ a formal lifestyle intervention in contrast to the studies included in the meta-analysis by Khera et al 25 all of which employed a diet and/or exercise cointervention. In addition, dose-ranging studies with dapagliflozin, indicating that urinary glucose excretion increases at higher doses of dapagliflozin, 26 and dose-ranging studies of liraglutide, 27 suggesting greater body weight loss with higher doses of a GLP-1RA, suggest that increased doses of dapagliflozin and exenatide QW in combination could potentially achieve more substantial body weight loss.
Thus, the full potential for weight reduction with this combination therapy is probably greater than described here, and needs to be Both the SGLT2 inhibitor empagliflozin 43, 44 and the GLP1-RAs liraglutide and semaglutide 45, 46 have recently been shown to substantially reduce fatal or nonfatal cardiovascular events in patients with T2D at high cardiovascular risk. In addition to cardiovascular metaanalyses for dapagliflozin 47 and exenatide, 48 dedicated outcome trials are ongoing for both of these compounds (DECLARE TIMI-58
[NCT01730534] and EXSCEL, 49 respectively).
The mechanisms leading to cardiovascular risk reduction are probably derived through a number of non-glycaemic effects for both SGLT2 inhibitors [50] [51] [52] and GLP-1RAs. 53, 54 In the current study among obese individuals without T2D, effects on SBP and body weight were similar to those with DAPA + ExQW among patients with T2D. 55 However, it is unknown whether such effects will translate into reductions in risk for future cardiovascular disease events in obese individuals without T2D or concurrent cardiovascular disease.
Pharmacological therapies for body weight loss have been associated historically with significant safety issues, leading to withdrawal of a number of agents. 7 However, for these therapies to be accepted, they must possess a good safety profile when administered over an extended time period with the aim of reducing body weight and associated long-term cardiometabolic risk. Even among currently approved treatments, careful patient selection is required to ensure safe use. 20 The separate safety profiles of dapagliflozin and exenatide have been evaluated in long-term clinical trials in patients with T2D for up to 4 years 56 and 6 years, 18 respectively. The principal AEs with dapagliflozin (UTIs and genital infections) and exenatide (gastrointestinal symptoms and injection-site reactions) tend to diminish with longerterm exposure. 57, 58 No unexpected AEs occurred with DAPA + ExQW dual therapy over 52 weeks of follow-up in this study. Discontinuations because of AEs with DAPA + ExQW (24.0% at 52 weeks) in the current study were comparable to previous trials with various weight loss drugs. 25 Moreover, in patients with T2D, the frequency of AEs was not overrepresented with DAPA + ExQW over 28 weeks compared with each agent administered alone. 55 The current study has limitations. It was a small, single-centre study without monotherapy comparator groups, making the effect size of each individual component difficult to assess. Placebo-treated participants with more body weight loss during 0 to 24 weeks showed a higher retention rate when entering the open-label extension, indicating selection bias. However, our primary ITT analysis used MMRM, minimizing bias in delayed-start clinical trials. 21 In this study, in which diet and exercise modification was not mandated or documented, dual therapy with DAPA + ExQW reduced and maintained body weight loss at approximately 5 kg after 1 year. This is similar to the placebo-corrected effect of currently approved pharmacotherapies for obesity, whereas we found a greater effect of DAPA + ExQW on reduction in glycaemic parameters, prediabetes prevalence and SBP. This suggests a potential role for prevention of T2D and cardiovascular disease in this population. No unexpected safety and tolerability issues were observed with the combination of DAPA + ExQW, and rates of discontinuation because of AEs and study attrition were comparable to those with approved pharmacotherapies for obesity.
Further studies evaluating long-term effects on body weight, glucose metabolism and cardiovascular risk with DAPA + ExQW in conjunction with formal diet and exercise interventions are warranted.
